Context Therapeutics (CNTX) investor relations material

Executive summary

• Focus shifted to advancing CTIM-76 and CT-202, discontinuing CT-95 development as of August 2026, with initial clinical readouts expected starting Q2 2027.

• CTIM-76 received FDA Fast Track designation for platinum-resistant ovarian cancer; interim Phase 1a data presented in June 2026 showed encouraging efficacy and safety.

• CT-202 Phase 1 trial approved in Australia, first patient dosing expected Q3 2026.

• Net loss for six months ended June 30, 2026 was $23.2 million; net loss widened to $14.6 million in Q2 2026 from $8.8 million in Q2 2025.

• Cash and cash equivalents were $43.0 million as of June 30, 2026, expected to fund operations into Q4 2027.

Financial highlights

• Research and development expenses rose 73% year-over-year to $19.5 million for the six months ended June 30, 2026; Q2 2026 R&D expenses were $12.5 million, mainly due to a $6.5 million BioAtla license amendment charge.

• General and administrative expenses increased 19% year-over-year to $4.8 million; Q2 2026 G&A expenses were $2.4 million.

• Interest income declined 50% year-over-year to $0.9 million due to lower cash balances.

• Net loss per share was $(0.24) for the six months ended June 30, 2026; $0.15 in Q2 2026.

• Cash and cash equivalents were $43.0 million as of June 30, 2026, down from $66.0 million at December 31, 2025.

Outlook and guidance

• Cash runway projected into Q4 2027 based on current operating plan.

• Additional capital will be required to support ongoing and future development activities.

• Initial Phase 1a data for CTIM-76 Q3W dosing expected in Q2 2027; Phase 1b trial initiation anticipated Q1 2027.

• Initial topline safety and efficacy data for CT-202 expected in H2 2027.